Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents.
Robertson AS, Majchrzak MJ, Smith CM, Gagnon RC, Devidze N, Banks GB, Little SC, Nabbie F, Bounous DI, DiPiero J, Jacobsen LK, Bristow LJ, Ahlijanian MK, Stimpson SA. Robertson AS, et al. Among authors: majchrzak mj. Neuromuscul Disord. 2017 Jul;27(7):635-645. doi: 10.1016/j.nmd.2017.05.009. Epub 2017 May 12. Neuromuscul Disord. 2017. PMID: 28554556 Free article.
Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.
Wager TT, Chappie T, Horton D, Chandrasekaran RY, Samas B, Dunn-Sims ER, Hsu C, Nawreen N, Vanase-Frawley MA, O'Connor RE, Schmidt CJ, Dlugolenski K, Stratman NC, Majchrzak MJ, Kormos BL, Nguyen DP, Sawant-Basak A, Mead AN. Wager TT, et al. Among authors: majchrzak mj. ACS Chem Neurosci. 2017 Jan 18;8(1):165-177. doi: 10.1021/acschemneuro.6b00297. Epub 2016 Oct 21. ACS Chem Neurosci. 2017. PMID: 27715007
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ. Kleiman RJ, et al. Among authors: majchrzak mj. J Pharmacol Exp Ther. 2012 May;341(2):396-409. doi: 10.1124/jpet.111.191353. Epub 2012 Feb 10. J Pharmacol Exp Ther. 2012. PMID: 22328573
Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.
Strick CA, Li C, Scott L, Harvey B, Hajós M, Steyn SJ, Piotrowski MA, James LC, Downs JT, Rago B, Becker SL, El-Kattan A, Xu Y, Ganong AH, Tingley FD 3rd, Ramirez AD, Seymour PA, Guanowsky V, Majchrzak MJ, Fox CB, Schmidt CJ, Duplantier AJ. Strick CA, et al. Among authors: majchrzak mj. Neuropharmacology. 2011 Oct-Nov;61(5-6):1001-15. doi: 10.1016/j.neuropharm.2011.06.029. Epub 2011 Jul 7. Neuropharmacology. 2011. PMID: 21763704
A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonists.
Lowe JA 3rd, DeNinno SL, Coe JW, Zhang L, Mente S, Hurst RS, Mather RJ, Ward KM, Shrikhande A, Rollema H, Johnson DE, Horner W, Gorczyca R, Tingley FD 3rd, Kozak R, Majchrzak MJ, Tritto T, Sadlier J, Shaffer CL, Ellerbrock B, Osgood SM, MacDougall MC, McDowell LL. Lowe JA 3rd, et al. Among authors: majchrzak mj. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4749-52. doi: 10.1016/j.bmcl.2010.06.142. Bioorg Med Chem Lett. 2010. PMID: 20663668
Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.
Rollema H, Hajós M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE, Chapin DS, Hoffmann WE, Johnson DE, McLean S, Freeman J, Williams KE. Rollema H, et al. Among authors: majchrzak mj. Biochem Pharmacol. 2009 Oct 1;78(7):813-24. doi: 10.1016/j.bcp.2009.05.033. Epub 2009 Jun 6. Biochem Pharmacol. 2009. PMID: 19501054
Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS. Schmidt CJ, et al. Among authors: majchrzak mj. J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20. J Pharmacol Exp Ther. 2008. PMID: 18287214
37 results